STOK compared with NGNE: revenue, margins and what each company keeps, and the suppliers and customers both name

STOKStoke Therapeutics, Inc.

Mkt capRevenueRevenue

NGNENeurogene Inc.

Mkt capRevenueRevenue

Compare

STOKStoke Therapeutics, Inc.

NGNENeurogene Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Co-movers

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Co-movers

daily closes · 500dMethod ›

Moved together

STOKwithNGNE

×0.66co-movement · NGNE on STOK · 500d

r 0.38scale to r 0.75

Shared co-movers5with STOKwith NGNE

DNLIDenali Therapeutics Inc.r 0.43r 0.39

SYRESpyre Therapeutics, Inc.r 0.41r 0.37

IMNMImmunome Inc.r 0.39r 0.37

RCKTRocket Pharmaceuticals, Inc.r 0.45r 0.36

IDYAIDEAYA Biosciences, Inc.r 0.40r 0.35

STOK, solidNGNE, hatched× = co-movement · βr = correlationBar = r to r 0.75Order: weaker of A and BSource: daily closes

STOKStoke Therapeutics, Inc.

26.30▼−0.19%· post 26.24

Mkt cap$1.7BRevenue$9MQ2 FY26Revenue$184MFY25

NGNENeurogene Inc.

27.61▼−4.20%· post 27.61

ClosedOct 30 '26

Mkt cap$621.3MRevenue$925,000Q2 FY24Revenue—

Compare

ClosedOct 30 '26

STOKStoke Therapeutics, Inc.

NGNENeurogene Inc.

26.30▼−0.19%post 26.24

Price

27.61▼−4.20%post 27.61

$1.7B

Mkt cap

$621.3M

Q2 FY26$9M

Revenue

$925,000Q2 FY24

FY25$184M

Revenue

—

STOK26.30▼−0.19%vsNGNE27.61▼−4.20%ClosedOct 30 '26